Cheetah Medical Set To Compete In Fast-Growing Hemodynamic Monitoring Market
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently, driven by rising cost pressures on hospitals, demographics, and new noninvasive alternatives to conventional hemodynamic monitoring technologies that require the insertion of an arterial line or pulmonary artery catheter.
You may also be interested in...
Edwards Lifesciences announced that it was acquiring private Dutch company BMEYE BV, the developer of a new noninvasive technology for hemodynamic monitoring. Noninvasive hemodynamic monitoring has long been “The Holy Grail” in critical care, and non-invasive technology opens up new applications and new markets for Edwards as well.
Generics Bulletin previews the most notable and anticipated events for October 2023.
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.